We work closely with industry partners at every stage of amyloidosis therapeutic development to advance the most promising ideas and accelerate the development of breakthrough treatments and get products to market faster.
We are committed to fostering critical collaborations with companies to support promising programs. Our unique relationships provides access to all stakeholders including research and clinical experts, patients, regulators and payers across the globe.
We partner with companies that wish to benefit from our unbiased expertise and extensive knowledge of the field to accelerate shared research goals to improve outcomes and quality of life for patients. We provide strategic consultation and develop partnerships across a number of different areas, both on individual and multi-company level.
Early in 2018 ARC hosted a research workshop. This meeting included disease experts from basic and translational research, academia, industry, and regulatory bodies. The purpose of the workshop was to define the most important research questions in systemic amyloidosis. The outcomes from this meeting will be written up and published as a white paper later this year, and form a blueprint for research most likely to make a significant, material contribution to improving patient outcomes.
Our corporate partners make critical contributions to the ARC’s mission while engaging with highly motivated audiences. Your support is crucial to growing, enhancing and delivering our high-impact programs to educate and engage the community.
This unique clinical trial matching tool is specifically designed to educate and engage amyloidosis patients to take part in trials and find treatment centers. It is successfully alerting patients to research opportunities and connecting them with trials. The insights on trial-ready patients help inform the design of more effective clinical trial and identify target populations for recruitment to specific studies. There are opportunities to partner on varying levels. View My Amyloidosis Pathfinder here.
ARC convenes industry partners that are engaged in developing therapeutics for systemic amyloidosis to come together in the pre-competitive space to address some of the most urgent issues we face.
On November 16, 2015, at the suggestion of the US Food and Drug Administration (FDA), the Amyloidosis Research Consortium (ARC) hosted an externally led Patient-Focused Drug Development meeting to share with the Agency and other stakeholders (e.g., industry) the perspectives of people living with systemic amyloidosis, its impact on their daily lives, and their perspectives on approaches to treating amyloidosis. The meeting was conducted in accordance with the Agency’s Patient-Focused Drug Development (PFDD) initiative, an FDA commitment under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V) to more systematically gather patients’ perspectives on their condition and available therapies to treat their condition.
Learn more about the patient-focused drug development meeting here
Learn more about the Voice of the Patient here
View the Voice of the Patient Report here